IoM's Errant Committee

This article was originally published in RPM Report

01 Sep 2006
News

Michael McCaughan @RPMReportMike michael.mccaughan@previsionpolicy.com

Executive Summary

An Institute of Medicine committee offers its recommendations on addressing medication errors. Stakeholders are eager to embrace process improvements-but the committee is on a quest to encourage fundamental changes in the entire drug development enterprise.

Already Registered? Sign in to continue reading.

New to Pink Sheet? Start a free trial today!

Table
View full table

Topics

ASK THE ANALYST
Email

Print
Bookmark
Share

Tags:

BioPharmaceutical Clinical Trials Leadership

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

PS080128

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

PS080128

All set! This article has been sent to my@email.address.

All fields are required. For multiple recipients, separate email addresses with a semicolon.

Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.

IoM's Errant Committee

News

Executive Summary

Related Content

Drug Safety Reform: Did FDA Buy Time or Trouble?

Drug Safety Reform: Did FDA Buy Time or Trouble?

Topics

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

Register

Ask The Analyst

Email Article

Sign In To Set a Search Alert